You can buy or sell ADAP and other stocks, options, ETFs, and crypto commission-free!
Adaptimmune Therapeutics plc American Depositary Shares, also called Adaptimmune Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Read More The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
52 Week High
52 Week Low
Stock Price, News, & Analysis for Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform.
Seeking AlphaFeb 28
Adaptimmune Therapeutics (ADAP) CEO James Noble on Q4 2018 Results - Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2018 Results Earnings Conference Call February 27, 2019 8:00 PM ET Company Participants Juli Miller - IR James Noble - CEO Helen Tayton-Martin - Chief Business Officer Adrian Rawcliffe - CFO Rafael Amado - President, Research and Development Conference Call Participants Jonathan Chang - SVB Leerink Peter Lawson - Sun Trust Robinson Michael Schmidt - Guggenheim Securities Marc Frahm - Cowen & Company Reni Benjamin - Raymond James Soumit Roy - Jones T...
Associated PressFeb 27
CORRECTING and REPLACING -- Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. PHILADELPHIA and OXFORD, United Kingdom, Feb. 27, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Adaptimmune Therapeutics plc (Nasdaq:ADAP), please note that the third subheadline should ...
Expected May 8, Pre-Market